Stefanie Flückiger-Mangual (left) and Julie Cherrington
September 20, 2023 05:29 AM EDT
Financing
Startups

Tol­re­mo rais­es $39M Se­ries A to ad­vance drug de­signed to dis­man­tle ear­ly can­cer de­fens­es

Ayisha Sharma

News Reporter

Tol­re­mo Ther­a­peu­tics has com­plet­ed a $39 mil­lion Se­ries A to fund a Phase I tri­al for its lead can­di­date in sol­id tu­mors. The com­pa­ny is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times